Glycomine
Developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist.
Launch date
Employees
Market cap
-
Enterprise valuation
$140—210m (Dealroom.co estimates Jun 2021.)
San Carlos California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$12.0m | Series A | ||
* | $33.0m | Series B | |
$35.0m | Series B | ||
Total Funding | $80.0m |
Related Content
Recent News about Glycomine
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.